Entellus Medical

2016 News Releases

Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
08/03/16Entellus Medical Announces Second Quarter 2016 Financial Results
PLYMOUTH, Minn., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (the “Company” or “Entellus Medical”) (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today reported its financial results for the quarter ended June 30, 2016. Recent Highlights and Accomplishments Revenue of $18.7 million in the second quarter o... 
07/27/16Entellus Medical to Present at the Canaccord Genuity Growth Conference
PLYMOUTH, Minn., July 27, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced the company plans to participate in the 36th Annual Growth Conference hosted by Canaccord Genuity in Boston, MA. Entellus Medical’s management is scheduled to present on Wednesday, August ... 
07/12/16Entellus Medical to Report Second Quarter 2016 Financial Results on August 3, 2016
Conference call scheduled for Wednesday, August 3, 2016 at 3:30pm CT / 4:30pm ET PLYMOUTH, Minn., July 12, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced that it will release its financial results for the second quarter 2016 after the close of trading on Wednesda... 
06/29/16Entellus Medical Acquires XeroGel™ from CogENT Therapeutics®, Strengthens Product Portfolio
Reiterates 2016 Financial Outlook PLYMOUTH, Minn., June 29, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL) today announced it has acquired and entered into an exclusive license for the XeroGel assets with CogENT Therapeutics, LLC for $11 million in cash.  Under terms of the agreements, Entellus has become the manufacturer of XeroGel and will continue to market and sell XeroGel to hospitals, offices, clinics and ambulatory surgery centers. This transaction delivers on Entellus’s... 
06/27/16Entellus Medical and Fiagon Announce Expanded Agreement to Include Hospital-Based Customers
Introduction of the Premium Fiagon Navigation System for hospital customers, complete with more advanced ENT and cranio-maxillofacial (CMF) applications PLYMOUTH, Minn. and AUSTIN, Texas, June 27, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL) and Fiagon NA Corporation announced today that they have expanded their agreement allowing Entellus to exclusively distribute Fiagon branded Navigation Systems and accessories in the United States and Canada.  The expanded agreement enabl... 
06/02/16Entellus Medical to Present at the William Blair Growth Stock Conference
PLYMOUTH, Minn., June 02, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced the company plans to participate in the 36th Annual Growth Stock Conference hosted by William Blair in Chicago, IL. Entellus Medical’s management is scheduled to present on Wednesday, June... 
05/23/16Entellus Medical Names Brent Moen Chief Financial Officer
PLYMOUTH, Minn., May 23, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced the appointment of Brent Moen as Chief Financial Officer and Corporate Secretary, effective immediately.  Thomas Griffin, the Company’s current CFO, is assuming the newly created position of V... 
05/19/16Entellus Medical Announces Presentation of Positive Clinical Study Results for XprESS in Pediatric Patients
Balloon Sinus Dilation Determined to be Safe and Effective for Children with CRS Aged Two Years and Older PLYMOUTH, Minn. and CHICAGO, May 19, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL) announced today that Dr. Zachary M. Soler, MD, MSc, Medical University of South Carolina, presented the results of a prospective, multicenter study of children with chronic rhinosinusitis (CRS) treated with the XprESS™ Multi-Sinus Dilation System. The results were presented at the Combined O... 
05/04/16Entellus Medical Announces First Quarter 2016 Financial Results
PLYMOUTH, Minn., May 04, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today reported its financial results for the quarter ended March 31, 2016.  Recent Highlights and Accomplishments Revenue of $16.9 million in the first quarter of 2016, an increase of 25% year-over-y... 
04/18/16Entellus Medical to Report First Quarter 2016 Financial Results on May 4, 2016
Conference call scheduled for Wednesday, May 4, 2016 at 3:30pm CT / 4:30pm ET PLYMOUTH, Minn., April 18, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced that it will release its financial results for the first quarter 2016 after the close of trading on Wednesday, ... 
02/24/16Entellus Medical Announces Fourth Quarter and Full Year 2015 Financial Results and Issues 2016 Financial Outlook
PLYMOUTH, Minn., Feb. 24, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today reported its financial results for the quarter and year ended December 31, 2015.  Recent Highlights and Accomplishments Achieved net revenue of $61.6 million in 2015, an increase of 26% year-o... 
02/10/16Entellus Medical to Report Fourth Quarter and Year-End 2015 Financial Results on February 24, 2016
Conference Call Scheduled for Wednesday, February 24, 2016 at 4:30pm ET PLYMOUTH, Minn., Feb. 10, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced that it will release its financial results for the fourth quarter and year-end 2015 after the close of trading on Wedn... 
01/28/16Entellus Medical to Present at the Leerink Partners 5th Annual Global Healthcare Conference
PLYMOUTH, Minn., Jan. 28, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced the company plans to participate in the Leerink Partners 5th Annual Global Healthcare Conference in New York, NY. Entellus Medical’s management is scheduled to present on Thursday, Februar...